LKT Labs

Biochemicals for Life Science Research

MLN8237

MLN8237

Product ID M4652
Cas No. 1028486-01-2
Purity ≥98%
Product Unit SizeCostQuantityStock
1 mg $118.40 In stock
5 mg $218.70 In stock
10 mg $337.40 In stock
Bulk Quote

Quicklinks

Description

MLN8237 inhibits aurora kinase A (AurA) preventing mitotic spindle formation and proper completion of mitosis. MLN8237 exhibits anticancer chemotherapeutic activity and is currently in clinical trials as a potential treatment for multiple myeloma, non-Hodgkin’s lymphoma, and chronic lymphocytic leukemia (CLL). In bladder cancer cells, MLN8237 induces cell cycle arrest, aneuploidy, and apoptosis; in animal models of bladder cancer, this compound inhibits tumor growth. Additionally, MLN8237 inhibits tumor growth of neuroblastomas in vivo as well. In HUVECs, MLN8237 decreases tubule formation and inhibits VEGF secretion, suggesting potential anti-angiogenic activity.

Product Info

Cas No.

1028486-01-2
Purity

≥98%
Formula

C27H20ClFN4O4
Formula Wt.

518.92
IUPAC Name

4-[[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-2-methoxybenzoic acid
Synonym

Alisertib
Solubility

DMSO 27 mg/mL (52.03 mM) Water Insoluble Ethanol Insoluble
Appearance

Pale Yellow Powder

Shipping and Storage

Store Temp

-20°C
Ship Temp

Ambient

Downloads

MSDS

M4652 MSDS PDF
Info Sheet

M4652 Info Sheet PDF

References

Romain C, Paul P, Kim KW, et al. Targeting Aurora kinase-A downregulates cell proliferation and angiogenesis in neuroblastoma. J Pediatr Surg. 2014 Jan;49(1):159-65. PMID: 24439602.

Kelly KR, Shea TC, Goy A, et al. Phase I study of MLN8237-investigational Aurora A kinase inhibitor-in relapsed/refractory multiple myeloma, Non-Hodgkin lymphoma and chronic lymphocytic leukemia. Invest New Drugs. 2013 Dec 20. [Epub ahead of print]. PMID: 24352795.

Zhou N, Singh K, Mir MC, et al. The investigational Aurora kinase A inhibitor MLN8237 induces defects in cell viability and cell-cycle progression in malignant bladder cancer cells in vitro and in vivo. Clin Cancer Res. 2013 Apr 1;19(7):1717-28. PMID: 23403633.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Related Products

  • N7200

    NS-11394

    GABA-A α5/3/2 positive modulator.

    ≥98%
  • T1298

    TDZD-8

    GSK-3β inhibitor.

    ≥98%
  • V1869

    Verbascoside

    Phenylpropanoid found in Castilleja, Verbena, V...

    ≥98%
  • J8800

    JW55

    TNKS1/2 inhibitor.

    ≥98%
  • L943721

    LXS-196

    Selective inhibitor of protein kinase C (PKC).<...

    ≥98%
  • D4873

    Meso-2,3-dimercaptosuccinic Acid

    Organosulfur, chelating agent.

    ≥98%
  • D1694

    Dexamethasone Acetate Monohydrate

    Steroid; glucocorticoid agonist.

    ≥98%
  • M1873

    S-(N-Methylsulfinylbutylthiocarbamoyl)-L-cysteine

    Sulforaphane-cysteine conjugate.

    ≥98%
  • D5746

    Dolasetron

    5-HT3 antagonist.

    ≥98%
  • T3041

    Thienylpropyl Isothiocyanate

    Thienylbutyl ITC analog.

    ≥98%
  • C000171

    C-171

    STING inhibitor

    ≥98%
  • G4479

    Glucagon (19-29), human

    Endogenous peptide hormone, glugagon fragment; ...

    ≥95%
  • A9818

    Azelastine Hydrochloride

    TRPV1 agonist, histamine H1 antagonist.

    ≥98%
  • T1679

    Tetracycline Hydrochloride

    Polyketide; protein translation inhibitor, mamm...

    ≥95%
  • L5769

    Lorglumide Sodium

    CCK antagonist.

    ≥98%
  • O9257

    16-Oxokahweol

    Synthetic kahweol derivative.

    ≥95%
  • A4802

    Amantadine Hydrochloride

    Viral M2 proton channel blocker, MAO-A, NET, NM...

    ≥98%
  • K0022

    K252b

    Staurosporine analog; PKC inhibitor.

    ≥98%
  • E2003

    Efavirenz

    Non-nucleoside RT inhibitor.

    ≥99%
  • A5313

    Andrographolide

    Labdane diterpene found in Andrographis; RLR (R...

    ≥98%